Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Pharmacokinetic Study of VAL-413 (Orotecan®) in Patients With Recurrent Pediatric Solid Tumors

NCT04337177 is registered in ClinicalTrials.gov with Valent Technologies, LLC as lead sponsor.

NCT NCT04337177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04337177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Pharmacokinetic Study of VAL-413 (Orotecan®) in Patients With Recurrent Pediatric Solid Tumors
Lead sponsor
Valent Technologies, LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 25, 2021
Completion date
December 31, 2026
Enrollment
20 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, hepatoblastoma, medulloblastoma, neuroblastoma, rhabdomyosarcoma, solid tumors